CLPBY Earnings Date: Nov 3, 2026 — Coloplast A/S
OTC · Healthcare · Medical Instruments & Supplies
Updated
When is CLPBY's next earnings date?
Coloplast A/S (CLPBY) is scheduled to report Q4 2026 earnings on Tuesday, November 3, 2026 at 5:00 AM ET (before market open). The consensus estimate is EPS of $0.09 on revenue of $1.12B.
How did CLPBY do in its last earnings report?
In its most recent report on Aug 18, 2026 (Q3 2026), Coloplast A/S posted EPS of $0.10 versus the $0.10 estimate, a beat of 2.0%. Revenue was $1.14B against a $1.11B estimate.
How much does CLPBY stock move after earnings?
CLPBY beat EPS estimates in 2 of its last 4 reported quarters.
About Coloplast A/S
Coloplast A/S, founded in 1954 and headquartered in Humlebæk, Denmark, operates as a global developer and marketer of intimate healthcare products and services. Its extensive reach spans Denmark, the United States, the United Kingdom, France, and numerous other international regions. The company's activities are organized into three primary segments: Chronic Care, Interventional Urology, and Wound & Skin Care. Within Chronic Care, Coloplast provides advanced ostomy solutions, including the SenSura Mio, recognized for its adaptable fit and discretion, alongside other SenSura offerings and Brava brand accessories. This segment also delivers continence care products such as Conveen Active urine bags, SpeediCath catheters for diverse users, and the Peristeen transanal irrigation system. The Wound & Skin Care division features innovative dressings like the conforming Biatain Silicone and the hydrocolloid Comfeel. Additionally, it offers a broad spectrum of skin care items, encompassing bathing and cleansing products, moisturizers, skin protectants, antifungal treatments, hand cleansers, odor control solutions, and the specialized InterDry system for managing skin folds. Finally, the Interventional Urology segment is dedicated to crafting and commercializing surgical devices that address a range of urological and gynecological conditions, such as urinary stone disease, benign prostatic hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-18 | Q3 2026 | 0.10 | 0.10 | +2.00% | $1.14B | ✅ Beat | — | — | — |
| 2026-05-12 | Q2 2026 | 0.09 | 0.10 | +7.78% | $1.11B | ✅ Beat | — | — | — |
| 2026-02-06 | Q1 2026 | 0.09 | 0.09 | +0.00% | $1.10B | ➖ Inline | — | — | — |
| 2025-11-04 | Q4 2025 | — | 0.07 | — | $1.09B | — | — | — | — |
| 2025-08-19 | Q3 2025 | — | 0.06 | — | $1.06B | — | — | — | — |
| 2025-05-06 | Q2 2025 | — | 0.06 | — | $976.6M | — | — | — | — |
| 2025-02-04 | Q1 2025 | 0.08 | 0.07 | -12.50% | $1.00B | ❌ Miss | +0.45% | +0.72% | -4.76% |
| 2024-11-05 | Q4 2024 | — | 0.08 | — | $1.02B | — | — | — | — |
Showing last 8 quarters.